Stifel affirms Biogen (Nasdaq: BIIB) at Hold after the company and Ionis Pharmaceuticals announced that nusinersen, their investigational treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE